 | In a comment letter to the Institute for Clinical and Economic Review (ICER), the Partnership to Improve Patient Care (PIPC) offered feedback on ICER’s draft evidence report for Myasthenia Gravis (MG). |
PIPC offered strong criticism of ICER’s model for its use of the discriminatory quality-adjusted-life-years (QALY) metric. The letter also highlights additional flaws in ICER’s report, including: (1) failing to accurately capture patient heterogeneity; (2) inaccurately capturing the MG patient experience; and (3) misrepresenting hospitalization costs for MG patients.
“ICER’s model does not paint a full picture of the value of these treatments to the patient or society,” wrote PIPC Chairman Tony Coelho. “We urge ICER to make appropriate revisions to its model and to clearly communicate these limitations in its final report so that payers are not tempted to create one-size-fits-all coverage restrictions for new MG treatments.”
“ICER’s model does not paint a full picture of the value of these treatments to the patient or society,” wrote PIPC Chairman Tony Coelho. “We urge ICER to make appropriate revisions to its model and to clearly communicate these limitations in its final report so that payers are not tempted to create one-size-fits-all coverage restrictions for new MG treatments.”
| icer_mg_final_for_submission.pdf |
